

Attorney Docket No.: 6169.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Knudsen et al

Application No.: 09/800,541

Group Art Unit: 1647

Filed: March 7, 2001

Examiner: Romeo, D.

For: Lowering Serum Lipids

RECEIVED

NOV 13 2002

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents  
Washington, DC 20231

Sir:


In response to the restriction requirement mailed October 2, 2002, Applicants respectfully elect the claims of Group I (claims 26-29 and 36-42) and the species Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>6</sup>-( $\gamma$ -Glu(N<sup>6</sup>-hexadecanoyl)))-GLP-I(7-37) for continued prosecution on the merits. All of the elected claims are readable on the species Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>6</sup>-( $\gamma$ -Glu(N<sup>6</sup>-hexadecanoyl)))-GLP-I(7-37).

Applicants reserve the right to pursue the subject matter of the claims of nonelected Groups II-VI in continuing applications.

It is believed that the claims are in condition for allowance, and a determination to that effect is earnestly solicited.

Respectfully submitted,

Date: November 4, 2002

  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800



23650

PATENT & TRADEMARK OFFICE